Search

IN FOCUS - VISION 2020 LINKS Programme: the contribution of health partnerships to reduction in blindness worldwide

As other articles in this series (IN FOCUS Apr 2020) demonstrate, the year 2020 is highly significant in the eye care field. Naming a global initiative ‘VISION 2020: The Right to Sight’ in 1999 was a daring way to focus...

#KnowYourDrops: breaking down barriers to poor compliance

Award-winning* #KnowYourDrops eye drop compliance campaign helps patients for World Glaucoma Week to achieve medicines optimisation in ophthalmology. The #KnowYourDrops campaign is fast becoming an internationally recognised model to help support healthcare professionals, with the provision of better tailored ophthalmic...

The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD

Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...

An update on inherited retinal disorders (part 1) – overview and assessment of inherited retinal disease

Part 2 of this topic can be found here Inherited Retinal Disease (IRD) is the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales and the second most common in childhood [1]....

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Optimising the ocular surface by managing meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is ubiquitous. Ocular surface inflammation and irritation are prevalent in most ophthalmology clinics: corneal, cataract, glaucoma, oculoplastic, paediatric, vitreo-retinal, medical retina and refractive surgery. These patients also represent roughly one third of those attending for emergency...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

The past and the future for paediatric ophthalmology

The past 25 years have seen remarkable advances in clinical eye care for children in the UK. This has led to both improved outcomes and better patient and family experiences. There have been substantial changes to patient pathways, major advances...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Innovations in ophthalmology: what can the innovations of the past teach us about tomorrow?

BUOS Prize Essay – 2nd prize winner for 2013 submissions Introduction An essay titled Innovations in Ophthalmology might choose to focus on the history; from cataract couching to femtosecond lasers, ophthalmology has had no shortage of topics worthy of discussion....